The Molecular Microscope Era: How Nanotech and Genomics Are Reshaping Cancer Detection and Beyond

From Diagnostic Blindness to Molecular Precision For decades, early-stage cancer detection and monitoring of treatment-resistant diseases were plagued by critical technological limitations. Traditional genetic testing methods, including Sanger sequencing and even early PCR-based diagnostics, were limited by poor sensitivity—often requiring more than 20–30% mutant allele frequency to detect a mutation. This meant that early-stage tumors…